← Leaderboards
Matt Westerman
Leidos Biomedical Research, Inc.
$8,377,026
Attributed
$8,377,026
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.1M · FY2015–18$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
Funding mix
By agency
NIH$8,377,026 · 1
By mechanism
N01$8,377,026 · 1
Top collaborators
No co-investigators on record.
Most similar at Leidos Biomedical Research, Inc.
Same institution · by research overlap
- David Heimbrook$2,362,140,846
- Leonard Freedman$1,216,107,431
- David Lindsay$51,337,878
- Gautam Mitra$3,186,514
- Leonard Freedmand$281,097,701
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsBaseVaccine CandidateNeutralizing AntibodySafetyChikungunyaServicesPhase I Clinical TrialsProductionPreclinical StudyCollaborationsCyclic GmpDisease OutbreaksChikungunya VirusClinical MaterialNational Institute Of Allergy And Infectious DiseaseAmericasFundingGovernmentClinical ResearchEfficacy TrialHealthy VolunteerImmunogenicityPrograms
Grant awards (5)
IGF::OT::IGF ADVANCE UNIVERSAL INFLUENZA VACCINE CANDIDATES BASED ON RBD-FERRITIN NANOPARTICLES$193,201
N01 · FY2018 · CA · contact PI
IGF::OT::IGF RESEARCH, DEVELOPMENT, PRODUCTION AND SUPPORT FOR CLINICAL TRIALS BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES (BNMABS)$67,104
N01 · FY2018 · CA · contact PI
ADVANCE CHIKUNGUNYA VACCINE CANDIDATES INTO LATER-PHASE CLINICAL TRIALS$47,255
N01 · FY2018 · CA · contact PI
Development and Production of membrane Proximal External Region (MPER)/ Anti-HIV broadly neutralizing antibodies (bNAbs) for prevention, therapy or cure$5,069,466
N01 · FY2015 · CA · contact PI
ADVANCE CHIKUNGUNYA VACCINE CANDIDATES INTO LATER-PHASE CLINICAL TRIALS$3,000,000
N01 · FY2015 · CA · contact PI